Last reviewed · How we verify
TJ004309
At a glance
| Generic name | TJ004309 |
|---|---|
| Sponsor | I-Mab Biopharma US Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors (PHASE2)
- A Phase I/II Study of TJ004309 for Advanced Solid Tumor (PHASE1, PHASE2)
- Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
- Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TJ004309 CI brief — competitive landscape report
- TJ004309 updates RSS · CI watch RSS
- I-Mab Biopharma US Limited portfolio CI